Education
About Us
Working with TipRanks
Follow Us
Orexo AB (SE:ORX)
:ORX
Top Page
Orexo AB
(OTC:ORX)
41Neutral
Orexo AB (ORX) vs. S&P 500 (SPY)
Market Cap
$514.42M
Dividend YieldN/A
Average Volume (3M)14.15K
Price to Earnings (P/E)―
Beta (1Y)0.26
Revenue Growth-3.57%
EPS Growth-185.36%
CountrySE
Employees110
SectorHealthcare
Sector Strength46
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.50
Shares Outstanding34,710,640
10 Day Avg. Volume14,919
30 Day Avg. Volume14,146
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-4.09
Price to Sales (P/S)0.00
P/FCF Ratio-13.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Orexo AB Business Overview & Revenue Model
Company DescriptionOrexo AB is a Swedish pharmaceutical company focused on the development, manufacturing, and commercialization of innovative pharmaceuticals and digital therapies. Primarily operating in the field of addiction treatment, Orexo is known for its expertise in developing products aimed at addressing opioid dependence and related conditions. The company's core products include proprietary formulations and digital solutions designed to improve patient outcomes and enhance the effectiveness of addiction therapies.
How the Company Makes MoneyOrexo AB generates revenue through the sale of its pharmaceutical products, particularly in the addiction treatment sector. The company's key revenue streams include the commercialization of its flagship products, such as Zubsolv, a sublingual tablet used for the treatment of opioid dependence. Orexo also earns income through licensing agreements and partnerships with other pharmaceutical companies, which allow for broader distribution and marketing of its products. Additionally, the company invests in digital therapeutics, offering subscription-based digital health solutions that complement traditional treatment methods, thereby creating an additional source of revenue.
Orexo AB Financial Statement Overview
Summary
Orexo AB's financial health is under strain, marked by declining revenues, negative profit margins, and a concerning balance sheet position with negative equity. The company faces liquidity challenges and may require strategic measures to stabilize its finances and return to profitability.Income Statement
Orexo AB has been experiencing a declining revenue trend with a revenue decrease of 7.66% from 2023 to 2024. The gross profit margin remains strong at 87.78% in 2024, yet the company faces significant challenges with profitability, as indicated by a negative net profit margin of -34.41% and a negative EBIT margin of -23.77%.35
Negative
Balance Sheet
The balance sheet reveals a concerning financial position with negative stockholders' equity of -21.23% and a high debt-to-equity ratio due to the negative equity. The company's liabilities exceed its assets, indicating financial instability and potential liquidity risks.20
Very Negative
Cash Flow
Orexo AB shows a challenging cash flow position with negative operating cash flow and free cash flow in 2024. The operating cash flow to net income ratio is less than 1, indicating inefficiencies in converting sales into actual cash flow. The free cash flow growth rate shows improvement from 2023 but remains negative.25
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 590.00M | 638.80M | 624.30M | 565.00M | 663.60M | Gross Profit |
| 517.90M | 549.90M | 521.70M | 486.10M | 598.00M | EBIT |
| -140.30M | -109.50M | -214.20M | -224.90M | -22.10M | EBITDA |
| 48.90M | -32.30M | -73.90M | -141.30M | 16.80M | Net Income Common Stockholders |
| -203.00M | -128.30M | -177.60M | -223.50M | -84.40M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 123.30M | 171.00M | 351.80M | 504.10M | 505.30M | Total Assets |
| 594.80M | 786.60M | 1.11B | 1.27B | 1.23B | Total Debt |
| 476.00M | 473.80M | 539.60M | 550.50M | 291.00M | Net Debt |
| 352.70M | 302.80M | 407.40M | 46.40M | -214.30M | Total Liabilities |
| 721.10M | 727.70M | 915.10M | 924.10M | 674.40M | Stockholders Equity |
| -126.30M | 58.90M | 193.90M | 349.60M | 558.50M |
| Cash Flow | Free Cash Flow | |||
| -37.20M | -113.90M | -180.50M | -281.80M | -172.90M | Operating Cash Flow |
| -32.60M | -95.00M | -156.60M | -229.00M | 16.80M | Investing Cash Flow |
| -5.30M | 200.80M | -234.70M | -52.90M | -189.10M | Financing Cash Flow |
| -15.50M | -70.10M | -21.40M | 250.60M | -111.30M |
Orexo AB Technical Analysis
Positive
14.98
Price Trends
14.89
Positive
16.68
Negative
15.23
Negative
Market Momentum
0.06
Negative
52.38
Neutral
42.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ORX, the sentiment is Positive. The current price of 14.98 is above the 20-day moving average (MA) of 14.50, above the 50-day MA of 14.89, and below the 200-day MA of 15.23, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 52.38 is Neutral, neither overbought nor oversold. The STOCH value of 42.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ORX.
Orexo AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.15B | 3.56 | -42.52% | 2.83% | 14.56% | -0.50% | |
50 Neutral | €400.36M | ― | -33.54% | ― | 72.05% | 33.68% | |
43 Neutral | kr373.35M | ― | -12.79% | ― | -6.43% | -323.52% | |
41 Neutral | $514.42M | ― | ― | -3.57% | -185.36% | ||
39 Underperform | €389.01M | ― | -194.31% | ― | 1643.36% | 50.36% | |
32 Underperform | €112.44M | ― | -186.40% | ― | ― | 24.47% |
* Healthcare Sector Average
Performance Comparison
SE:ORX
Orexo AB
14.98
-4.02
-21.16%
SE:ACTI
Active Biotech AB
0.09
-0.15
-62.18%
SE:INTEG.B
Integrum AB Class B
17.50
-37.30
-68.07%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
7.29
-8.31
-53.27%
SE:BRAIN
BrainCool AB
1.55
-0.09
-5.48%
Orexo AB Earnings Call Summary
Earnings Call Date:May 06, 2025
(Q3-2024)
| % Change Since: 3.31%|
Next Earnings Date:Jul 16, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed view with notable achievements in ZUBSOLV demand stabilization in the Commercial segment and promising developments in the AmorphOX platform. However, these were offset by challenges such as the decline in ZUBSOLV revenues, delays in OX124 approval, and increased legal costs, which impacted financial performance and raised liquidity concerns.Q3-2024 Updates
Positive Updates
ZUBSOLV Growth in Key Segment
ZUBSOLV showed stabilization in demand with growth in the Commercial segment year-over-year and quarter-over-quarter. The Commercial segment grew by 22% from the previous year, which is significant for profitability since it's more profitable than Medicaid and Medicare segments.
Successful Human Factor Study for OX124
Orexo completed a new Human Factor study for OX124, which was successful in addressing issues raised by the FDA regarding instructions for use.
AmorphOX Platform Opportunities
The AmorphOX platform has continued to show potential with ongoing feasibility projects in various chemical structures, including vaccines and biologics, indicating a stable formulation across small molecules and peptides.
Positive EBITDA Outlook
Orexo maintained a high gross margin of 86% and expects to achieve a positive EBITDA for the full year, despite current challenges.
Negative Updates
ZUBSOLV Revenue Decline
ZUBSOLV net revenues decreased by 6.7% year-over-year due to a weaker USD FX rate, declines in public demand, and an inventory destocking effect.
OX124 Approval Delay
OX124's FDA approval is delayed as additional tests and manufacturing adjustments are needed, impacting the launch timeline.
Legal and Investigation Costs
Higher legal costs were incurred due to the DOJ investigation and the ongoing ZUBSOLV patent dispute, impacting financial performance.
Cash Flow and Liquidity Concerns
Cash and cash equivalents decreased by SEK 25 million from the end of Q2, with cash flow from operating activities at minus SEK 13.4 million, raising concerns about liquidity.
Company Guidance
During Orexo's Q3 2024 earnings call, CEO Nikolaj Sørensen and CFO Frederik Jarrsten provided detailed guidance on various financial and operational metrics. The company's total revenue for the quarter was approximately SEK 136 million, with ZUBSOLV contributing SEK 131 million, marking a 6.7% year-over-year decline due to a weaker USD FX rate and reduced demand from the public sector. However, the Commercial segment exhibited robust growth, increasing by 22% from the previous year, despite a slight decline in Medicaid. Orexo's gross margin remained high at 86%, and operating expenses were reduced by 15% compared to the previous year. The company anticipates positive EBITDA for the full year, although inventory adjustments and potential DOJ investigation settlements could impact future financial results. Sørensen highlighted the importance of the upcoming FDA meeting regarding OX124 and expressed optimism about the stabilization in ZUBSOLV demand, particularly in the Commercial segment, which is more profitable. The company is also exploring strategic options to enhance its equity position and leverage its AmorphOX platform for future growth.Orexo AB Corporate Events
Orexo Appoints Friedrich von Bohlen as New Chairman of the Board
May 9, 2025
Orexo AB has appointed Friedrich von Bohlen as the new chairman of the board, succeeding James Noble. With over 25 years of experience in the biotech industry, von Bohlen brings a wealth of expertise to Orexo, which is poised for an exciting future centered around its AmorphOX® technology platform. The transition marks a strategic step for Orexo, aiming to create sustainable value for shareholders, patients, and partners, while acknowledging Noble’s contributions to the company’s financial stability and strategic development.
Orexo AB Annual General Meeting 2025: Key Resolutions and Strategic Initiatives
May 8, 2025
Orexo AB’s annual general meeting on May 8, 2025, resulted in the re-election of its board members and auditor, Ernst & Young Aktiebolag. The meeting also approved several key resolutions, including the authorization to issue new shares and repurchase own shares, aimed at enhancing corporate flexibility and capital usage. Additionally, the company adopted new articles of association to allow postal voting and the issuance of class C shares, reflecting strategic measures to strengthen its market position and shareholder engagement.
Orexo AB Reports Stable Q1 2025 Revenues and Promising Product Developments
May 6, 2025
Orexo AB’s Q1 2025 interim report reveals stable net revenues of SEK 146.2 million amidst a volatile market, though EBITDA decreased to SEK 5.9 million. The company showed positive clinical data for its nasal powder-based epinephrine product and converted future royalties for an endometriosis treatment into shares in Gesynta Pharma. Additionally, Orexo announced promising in-vivo data for an intranasal vaccine developed with Abera Bioscience, potentially enhancing its market position.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.